CB11, a novel PPARγ agonist, has emerged as a potential anti-cancer drug in targeting therapy for non-small cell lung cancer (NSCLC), demonstrating efficacy in overcoming radioresistance in NSCLC [146]. The gene discussed is PPARG; the disease is non-small cell lung carcinoma.